Literature DB >> 12518322

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.

Alexander Haese1, Markus Graefen, Charlotte Becker, Joachin Noldus, Jared Katz, Ilias Cagiannos, Michael Kattan, Peter T Scardino, Edith Huland, Hartwig Huland, Hans Lilja.   

Abstract

BACKGROUND: In recent studies serum levels of human glandular kallikrein 2 (hK2) demonstrated significant differences in pathologically organ-confined versus non-organ-confined prostate cancer (PCa). In this study we investigated whether hK2 adds independent information when considered together with traditionally used parameters to predict organ confined (pT2a/b) PCa.
METHODS: Serum levels of hK2, total and free prostate-specific antigens (PSA) were obtained one day before radical prostatectomy in 245 consecutive men. These were included with clinical stage and biopsy Gleason grade into univariate analysis and multivariate logistic regression models.
RESULTS: pT2a/b PCa was found in n = 148 patients. In univariate analysis all preoperative parameters demonstrated significant association with the presence of pT2a/b PCa. Using multivariate logistic regression model hK2 (P = 0.022), clinical stage (P < 0.0001), and Gleason grade (P < 0.0001) were independent predictors of pT2a/b PCa whereas PSA (P = 0.3) was not. In bootstrap corrected logistic regression based nomograms the addition of hK2 density marginally enhanced predictive accuracy when PSA, PSA density, clinical stage, and Gleason grade were considered (AUC = 0.879 without hK2 density and 0.883 with hK2 density).
CONCLUSIONS: hK2 and hK2 density could independently predict pT2a/b PCa. However, improvement in predictive accuracy was marginal when nomograms based on traditional variables were complemented with this serum marker. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12518322     DOI: 10.1002/pros.10180

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.

Authors:  Thomas Steuber; Andrew J Vickers; Alexander Haese; Charlotte Becker; Kim Pettersson; Felix K-H Chun; Michael W Kattan; James A Eastham; Peter T Scardino; Hartwig Huland; Hans Lilja
Journal:  Int J Cancer       Date:  2006-03-01       Impact factor: 7.396

Review 2.  Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.

Authors:  H Ballentine Carter
Journal:  Asian J Androl       Date:  2012-02-20       Impact factor: 3.285

3.  Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer.

Authors:  Manish Kohli; Paul G Rothberg; Changyong Feng; Edward Messing; Jean Joseph; Sreevidya Sadasiva Rao; Allison Hendershot; Deepak Sahsrabudhe
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 4.  Prognostic determinants in prostate cancer.

Authors:  Neil E Martin; Lorelei A Mucci; Massimo Loda; Ronald A Depinho
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

5.  Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer.

Authors:  Jane Bayani; Miltiadis Paliouras; Chris Planque; Shannon J C Shan; Cassandra Graham; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2008-07-22       Impact factor: 6.603

6.  Newer potential biomarkers in prostate cancer.

Authors:  Jonathan L Wright; Paul H Lange
Journal:  Rev Urol       Date:  2007

Review 7.  The Use of Biomarkers in Prostate Cancer Screening and Treatment.

Authors:  Ashley V Alford; Joseph M Brito; Kamlesh K Yadav; Shalini S Yadav; Ashutosh K Tewari; Joseph Renzulli
Journal:  Rev Urol       Date:  2017

8.  Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.

Authors:  Sven Wenske; Ruslan Korets; Angel M Cronin; Andrew J Vickers; Martin Fleisher; Howard I Scher; Kim Pettersson; Bertrand Guillonneau; Peter T Scardino; James A Eastham; Hans Lilja
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

Review 9.  Kallikreins as biomarkers for prostate cancer.

Authors:  Sung Kyu Hong
Journal:  Biomed Res Int       Date:  2014-04-07       Impact factor: 3.411

10.  Role of CYP3A5 in Modulating Androgen Receptor Signaling and Its Relevance to African American Men with Prostate Cancer.

Authors:  Priyatham Gorjala; Rick A Kittles; Oscar B Goodman; Ranjana Mitra
Journal:  Cancers (Basel)       Date:  2020-04-17       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.